A novel platform for radioimmunotherapy: Extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 20, Issue 4, 2005, Pages 457-466

  Lindén, Ola ^a   Kurkus, Jan ^a   Garkavij, Michael ^a   Cavallin Ståhl, Eva ^a   Ljungberg, Michael ^a   Nilsson, Rune ^b   Ohlsson, Tomas ^a   Sandberg, Bengt ^b   Strand, Sven Erik ^a   Tennvall, Jan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Mitra Medical AB   (Sweden)

Author keywords

90yttrium; Extracorporeal adsorption; Lymphoma; Radioimmunotherapy; Rituximab

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; AVIDIN; IBRITUMOMAB TIUXETAN; INDIUM 111; RITUXIMAB; RITUXIMAB BIOTIN IN 111; RITUXIMAB BIOTIN Y 90; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; ARTICLE; B CELL LYMPHOMA; BIOTINYLATION; BLOOD CLOTTING; CLINICAL ARTICLE; HEMATOLOGIC DISEASE; HEMATOLOGICAL PARAMETERS; HUMAN; IMMUNOSCINTIGRAPHY; MANTLE CELL LYMPHOMA; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY;

ADSORPTION; ANTIBODIES, MONOCLONAL; BIOTIN; BIOTINYLATION; CELL LINE, TUMOR; CLINICAL TRIALS; HEMADSORPTION; HUMANS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; KIDNEY; LIVER; LYMPHOMA, B-CELL; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; YTTRIUM RADIOISOTOPES;

EID: 24044495553     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2005.20.457     Document Type: Article

References (26)

1. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825.
2. Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003; 21:3051.
3. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine 1 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918.
4. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998;16:3270.
5. Witzig TE, White CA, Gordon LI, et al. Final results of a randomized controlled study of the Zevalin radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL. ASH 2000, San Francisco, CA, December 1-5, 2000. In: ASH. 2000:831a.
6. Davis TA, Kaminski MS. Results of a randomized study of Bexxar (tositumomab and Iodine 1 131 tositumomab) versus unlabeled tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma (NHL). ASH 2001, Orlando, FL, December 7-11, 2001. In: ASH; 2001. Blood; 2001:843a.
7. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study. Blood 2004;103:4429.
8. Koral KF, Dewaraja Y, Clarke LA, et al. Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma; Preliminary report. Cancer Biother Radiopharm 2000;15:347.
9. Hindorf C, Linden O, Stenberg L, et al. Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients. Clin Cancer Res 2003;9:4003S.
10. Hartmann Siantar CL, DeNardo GL, DeNardo SJ, Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy. J Nucl Med 2003; 44:1322.
11. Chen JQ, Strand SE, Tennvall J, el al. Extracorporeal immunoadsorption compared to avidin chase; Enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96. J Nucl Med 1997; 38:1934.
12. Garkavij M, Tennvall J, Strand SE, et al. Immunotargeting of syngeneic rat tumor with 125ChBR96-biotin monoclonal antibody using whole blood immunoadsorption (WBIA), J Nucl Med 1997;38:895.
13. Behr TM, Griesinger F, Riggert J, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin's lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 2002; 94:1363.
14. Turner JH, Martindale AA, Boucek J, et al. 131I-Anti-CD20 radioimmunotherapy of relapsed or refractory non-Hodgkin's lymphoma: A phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm 2003;18:513.
15. Wilbur DS, Chyan MK, Hamlin DK, et al. Trifunctional conjugation reagents. Reagents that contain a biotin and a radiometal chelation moiety for application to extracorporeal affinity adsorption of radiolabeled antibodies. Bioconjug Chem 2002;13:1079.
16. Wang ZM, Martensson L, Nilsson R, et al. Blood pharmacokinetics of various monoclonal antibodies labeled with a new trichelating reagent for simultaneous conjugation with DOTA and biotin prior to radiolabeling. Clin Cancer Res 2005;in press.
17. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793.
18. Sjogreen K, Ljungberg M, Strand SE. An activity quantification method based on registration of CT and whole-body scintillation camera images, with application to 131I. J Nucl Med 2002;43:972.
19. Grillo-Lopez AJ, Cheson BD, Horning SJ, et al. Response criteria for NHL: Importance of "normal" lymph node size and correlations with response rates. Ann Oncol 2000;11:399.
20. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974.
21. Paganelli G, Chinol M. Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods? Ear J Nucl Med Mol Imaging 2003;30:773.
22. Barbet J, Kraeber-Bodere F, Vuillez JP, et al. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Blather Radiopharm 1999;14:153.
23. Goldenberg DM, Chang CH, Sharkey RM, et al. Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 2003;30:777.
24. Rossi Norrlund R, Ullen A, Sandstrom P, et al. Dosimetry of fractionated experimental radioimmunotargeting with idiotypic and anti-idiotypic anticytokeratin antibodies. Cancer 1997;80:2681.
25. Wong JYC, Chu DZ, Yamauchi DM, et al. A phase I radioimmunotherapy trial evaluating 90Yttrium-labeled anticarcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res 2000;6:3855.
26. Vallabhajosula S, Kuji I, Harnacher KA, et al. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: Prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med 2005;46:634.